The present invention relates to compounds of formula I:
and pharmaceutically acceptable salts, stereoisomers or tautomers thereof
which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus
useful for the treatment of cancer, inflammatory diseases, reperfusion
injuries, ischemic conditions, stroke, renal failure, cardiovascular
diseases, vascular diseases other than cardiovascular diseases, diabetes,
neurodegenerative diseases, retroviral infection, retinal damage or skin
senescence and UV-induced skin damage, and as chemo- and/or
radiosensitizers for cancer treatment.